DETECTION OF INDIVIDUAL T-CELL REACTION PATTERNS AGAINST TUMOUR-ASSOCIATED ANTIGENS (TAAS) IN TUMOUR PATIENTS AS A BASIS FOR THE INDIVIDUALIZED THERAPEUTIC VACCINATION OF PATIENTS

摘要

The present invention relates to a method for identifying the preferential target antigens of anti-tumoral T-cells of a tumor patient, comprising: a) providing T-cells from the blood of at least one tumor patient, b) providing dendritic cells (DCs) and/or B-lymphocytes (BLCs) that are autologous of the tumor patient, wherein the DCs and BLCs have first been transfected with a selection of mRNAs, which code T-cell immunogenic tumor-associated antigens (TAA), and express the same, c) bringing the T-cells in contact with the DCs and/or BLCs, d) identifying those T-cells, which recognize the antigens of the DCs and/or BLCs, and e) identifying the preferential target antigens of anti-tumoral T-cells of the at least one tumor patient based on the T-cells, which recognize the antigens of the DCs and/or BLCs. The method may also comprise the expansion of the T-cells, which recognize antigens of the DCs and/or BLCs. The present invention further relates to a method for the production of an individualized tumor vaccine, or an individualized tumor therapeutic agent, and corresponding methods for the treatment of a tumorous disease utilizing the individualized tumor vaccine, or the individualized tumor therapeutic agent.